Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
2.1 SEK | +5.00% | +19.73% | +18.51% |
Sales 2021 | 844K 77.31K | Sales 2022 | 1.14M 105K | Capitalization | 595M 54.52M |
---|---|---|---|---|---|
Net income 2021 | -156M -14.29M | Net income 2022 | -168M -15.39M | EV / Sales 2021 | 1,710 x |
Net cash position 2021 | 254M 23.28M | Net cash position 2022 | 68.47M 6.27M | EV / Sales 2022 | 460 x |
P/E ratio 2021 |
-10.9
x | P/E ratio 2022 |
-3.54
x | Employees | 11 |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 75.52% |
Latest transcript on Immunovia AB
1 day | +5.25% | ||
1 week | +18.87% | ||
Current month | +52.41% | ||
1 month | +57.72% | ||
3 months | +14.31% | ||
6 months | +279.09% | ||
Current year | +17.66% |
Managers | Title | Age | Since |
---|---|---|---|
Jeff Borcherding
CEO | Chief Executive Officer | - | - |
Director of Finance/CFO | 62 | 22-03-31 | |
Karl Stone
COO | Chief Operating Officer | 61 | 23-02-28 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 70 | 16-12-08 | |
Peter Andersen
CHM | Chairman | 67 | 19-12-31 |
Michael Löfman
BRD | Director/Board Member | - | 23-05-21 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-26 | 2.1 | +5.00% | 909 873 |
24-04-25 | 2 | -4.76% | 689,247 |
24-04-24 | 2.1 | +9.72% | 1,041,782 |
24-04-23 | 1.914 | -7.31% | 1,067,817 |
24-04-22 | 2.065 | +17.73% | 3,201,853 |
Delayed Quote Nasdaq Stockholm, April 26, 2024 at 08:51 am EDT
More quotes1st Jan change | Capi. | |
---|---|---|
+17.66% | 8.31M | |
-13.48% | 18.55B | |
-46.15% | 2.65B | |
+14.09% | 1.81B | |
-3.39% | 1.61B | |
+21.24% | 1.21B | |
-10.58% | 1.03B | |
-21.72% | 896M | |
-7.73% | 680M | |
-17.56% | 686M |
- Stock Market
- Equities
- IMMNOV Stock